ProQR Therapeutics Q3 2024 Earnings Report $1.19 +0.06 (+5.31%) As of 02:09 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast ProQR Therapeutics EPS ResultsActual EPS-$0.11Consensus EPS -$0.12Beat/MissBeat by +$0.01One Year Ago EPSN/AProQR Therapeutics Revenue ResultsActual Revenue$4.22 millionExpected Revenue$4.75 millionBeat/MissMissed by -$530.00 thousandYoY Revenue GrowthN/AProQR Therapeutics Announcement DetailsQuarterQ3 2024Date11/7/2024TimeBefore Market OpensConference Call DateThursday, November 7, 2024Conference Call Time9:30AM ETUpcoming EarningsProQR Therapeutics' Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Earnings HistoryPRQR ProfilePowered by Remove Ads Earnings DocumentsPress Release(8-K) ProQR Therapeutics Earnings HeadlinesProQR Therapeutics Advances RNA Editing PipelineApril 3, 2025 | tipranks.comProQR Therapeutics Full Year 2024 Earnings: Misses ExpectationsMarch 15, 2025 | uk.finance.yahoo.comHas Trump finally met his match?Trump is making bold moves before even stepping back into the White House — securing border deals, brokering peace talks, and targeting sanctuary city funding. But according to 33-year Wall Street veteran Dylan Jovine, even Trump may not be able to fix what’s coming. Jovine believes there are five cracks forming in the U.S. economy — big enough to spark a 50% market crash, a 40% real estate plunge, and a surge in unemployment. That’s why he’s moved seven figures of his own money into a “safe haven” asset favored by names like Buffett, Musk, and Ackman. He’s released an emergency briefing explaining why the next 90 days could be critical for investors. April 9, 2025 | Behind the Markets (Ad)ProQR Therapeutics price target raised to $12 from $10 at H.C. WainwrightMarch 14, 2025 | markets.businessinsider.comProQR Therapeutics N.V.: ProQR Announces Year End 2024 Operating and Financial ResultsMarch 14, 2025 | finanznachrichten.deProQR Therapeutics files to sell 3.52M ordinary shares for holdersMarch 14, 2025 | markets.businessinsider.comSee More ProQR Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ProQR Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ProQR Therapeutics and other key companies, straight to your email. Email Address About ProQR TherapeuticsProQR Therapeutics (NASDAQ:PRQR) N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.View ProQR Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Lamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go Higher Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)The Goldman Sachs Group (4/14/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
